Product Images Eptifibatide

This appears to be a chart displaying the percent of patients with events for two treatments over a period of time (in days). The treatments are "Eptifibatide" and "Placebo." The chart shows that, after 20 days, the percent of patients with events is significantly lower for the Eptifibatide treatment (approximately 10%) compared to the Placebo treatment (approximately 14%). However, it is difficult to determine what type of events are being measured without further context.*

This is a description of a medication called Eptifibatide, which is administered via injection. It comes in a single-dose vial containing 20 mg of the medication per 10 ml of solution, with a total volume of 110 mL. The manufacturer is Hainan Shuangeheng Pharmaceuticals Co. Ltd. located in China, and it is distributed in the United States by Athenes, based in Schaumburg IL. The medication is intended for intravenous use only and is used for weight-adjusted bolus dosing. Storage directions advise to keep it refrigerated and it is recommended to use within three months from the date of production, and to discard any unused portions.*